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2 ABBREVIATIONS 
 
AC                adenylyl cyclase 
CCPA                          2-chloro-N
6
-cyclopentyladenosine      
2-CdA                         2-chloro-2’-deoxyadenosine (cladribine)                    
CHA                            N
6
-cyclohexyladenosine 
CGS 21680                  2-p-(2-carboxyethyl)phenylamino-5'-N-  
                                     ethylcarboxamidoadenosine 
2-ClADO                     2-chloroadenosine 
Cl-IB MECA               2-chloro-N
6
-(3-iodobenzyl)-adenosine-5′-N-methyluronamide 
CPA                             N
6
-cyclopentyladenosine  
DBU                             diazabicyclo[5.4.0]undec-7-ene 
DEPT                           distortionless enhancement by polarization transfer 
DMF                            N,N-dimethylformamide 
DMSO                         dimethylsulfoxide 
DPMA                         N
6
-(2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl)-
adenosine 
GR79236                     N-[1S-trans-2-hydroxycyclopentyl]adenosine 
IB-MECA                    N
6
-(3-iodobenzyl)-adenosine-5′-N-methyluronamide 
iBu                               isobutyl 
MECA                         5'-(N-methylcarboxamido)adenosine  
Me3SiOTf                    trimethylsilyltrifluoromethane sulphonate 
NECA                         5'-(N-ethylcarboxamido)adenosine 
PAPA-APEC              2-[4-[2-[2-[(4-aminophenyl)methylcarbonylamino]ethylcarbo-   
                                    nyl]ethyl]phenyl]ethylamino-5'-N-ethylcarboxamido adenosine                                                         
PLC                             phospholipase C 
PNS                             peripheral nervous system 
R-PIA                          N
6
-(2-phenylisopropyl)adenosine 
RT-PCR                      reverse transcription-polymerase chain reaction 
TMS                            tetramethylsilane 
TMSOTf                     trimethylsilyltrifluoromethane sulphonate  
WRC-0470                  2-cyclohexylmethylidenehydrazinoadenosine 
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3 THE INTRODUCTION 
 
Extracellular purines (adenosine, ADP, and ATP) and pyrimidines (UDP and UTP) are 
important signalling molecules that mediate diverse biological effects via cellsurface 
receptors termed purine receptors. 
There are two main families of purine receptors, adenosine or P1 receptors, and P2 
receptors, recognizing primarily ATP, ADP, UTP, and UDP. Adenosine/P1 receptors 
have been further subdivided, according to convergent molecular, biochemical, and 
pharmacological evidence into four subtypes; A1, A2A, A2B, and A3. 
Adenosine affects a wide variety of physiological functions by acting on central nervous, 
cardiovascular, immune, and hormonal systems; adenosine is also able to inhibit 
lipolysis, platelet aggregation, and neurotransmitter release from nerve endings and to 
potentiate histamine release from mast cells.
1
 
The adenosine actions are mediated by membrane receptors coupled to guanyl 
nucleotide-binding proteins (G-proteins). These receptors are integral membrane proteins 
with seven transmembrane domains made of hydrophobic amino acids units, each 
believed to constitute an α-helix of approximately 21 to 28 amino acids. The N-terminal 
of the protein lies on the extracellular side and the C-terminal on the cytoplazmatic side 
of the membrane.
2 
Receptor occupation promotes interaction between the receptor and 
the G protein on the interior surface of the membrane. This induces an exchange of GDP 
for GTP on the G protein α subunit and dissociation of the α subunit from the βγ 
heterodimer. Depending on its isoform, the GTP-α subunit complex mediates 
intracellular signaling either indirectly by acting on effector molecules such as adenylyl 
cyclase (AC) or phospholipase C (PLC), or directly by regulating ion channel or kinase 
function (Fig. 1).
3
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Figure 1.  Mechanism of G Protein coupling.
3
  
 
A1 and A3 receptors are coupled to a variety of second-messenger systems, including 
inhibition of adenylyl cyclase, inhibition or stimulation of phosphoinositol turnover, 
activation of guanylyl cyclase, and, in the case A1 receptors, activation of potassium 
channels and inhibition of calcium influx, while activation of A2A and A2B receptors 
stimulates adenylyl cyclase.
 
Highly selective ligands as agonists/antagonists for adenosine receptors have been 
developed. However, till now, all known adenosine agonists are closely related to the 
chemical structure of adenosine itself. Substitution at N
6
 or C2 may enhance affinity and 
may impart A1/A2/A3 selectivity. Other modifications of the adenine moiety usually lead 
to inactive or, few, active compounds.
 
Structure-activity relationship studies have pointed out that the ribose recognition 
domain of adenosine and adenosine analogues contributes strongly to the affinity for 
adenosine receptors. Among ribose modifications, replacement of hydrogen atoms of the 
ribose ring with a methyl group in adenosine and adenosine analogues afforded 
compounds with various affinity and selectivity.  The introduction of a methyl group at 
the C-2´ position in adenosine resulted in decrease of affinity, particularly at A2A and A3. 
However, when this modification was combined with N
6
-substitution with groups that 
 8 
induce potency and selectivity at the A1 receptors, the selectivity for A1 vs A2A and A3 
was increased.
4 
Replacement of the –CH2OH group of adenosine analogoues with an N-alkyl-5´-
carboxamide group (5´-uronamide modification) results in potent agonists. The highest 
agonist activity of the adenosine 5´-carboxamides is shown by those with small alkyl 
groups or cyclopropyl group. Depending on the substituents at N
6
 or C2 positions of the 
adenine moiety the adenosine-5´-uronamide analogues have been reported to enhance the 
affinity as agonists at A2A or A3 adenosine receptors.
5 
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4 AIM OF WORK 
 
My laboratory work was concentrated on the synthesis of adenosine analogues.  
There are different possibilities for modifications: they could be on the sugar or on the 
base. We wanted to synthesize different modified nucleobases containing chlorine by 
reaction of 2,6-dichloropurine and to get N9 isomers. A following work will have to find 
successful way of deprotection. 
Also several reaction conditions and methods in my work should be optimized. 
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5 THE THEORETICAL PART 
 
5.1 Adenosine/P1 Receptors 
           
N
N
N
N
NH2
O
OH
OHOH
  adenosine
 
5.1.1  A1 Receptor 
 
A: Distribution and Biological Effects 
A1 receptors are widely distributed in most species and mediate diverse biological 
effects.  
A1 receptors are particularly ubiquitous within the central nervous system (CNS), with 
high levels being expressed in the cerebral cortex, hippocampus, cerebellum, thalamus, 
brain stem, and spinal cord. 
A1 receptor mRNA is widely distributed in peripheral tissues having been localized in 
vas deferens, testis, white adipose tissue, stomach, spleen, pituitary,adrenal, heart, aorta, 
liver, eye, and bladder. Only very low levels of A1 mRNA are present in lung, kidney, 
and small intestine.
6
 
It is now well established that adenosine is released from biological tissues during 
hypoxia and ischemic conditions. 
One of its effects is to reduce neuronal activity and thereby oxygen consumption; thus it 
acts as a neuroprotective agent. A significant part of these effects seems to be mediated 
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by the A1 receptor. A1 receptors are located pre and postsynaptically on cell bodies, and 
on axons, where they mediate inhibition of neurotransmission by decreasing transmitter 
release, hyperpolarizing neuronal membranes and reducing excitability, and altering 
axonal transmission. Adenosine can also exert behavioral effects: adenosine actions at A1 
receptors have been implicated in sedative, anticonvulsant, anxiolytic, and locomotor 
depressant effects. 
A1 receptors mediate cardiac depression through negative chronotropic, dromotropic, and 
inotropic effects. Slowing of the heart rate occurs via A1 receptors on sinoatrial and 
atrioventricular nodes causing bradycardia and heart block, respectively, while the 
inotropic effects include a decrease in atrial contractility and action potential duration. 
This aspect of A1 receptor mediated effects has found application in the clinical use of 
adenosine to treat supraventricular tachycardia, and in the use of adenosine receptor 
antagonists in the treatment of bradyarrhythmias. 
In the kidney, activation of A1 receptors mediates diverse effects including 
vasoconstriction (principally of the afferent arteriole), a decrease in glomerular filtration 
rate, mesangial cell contraction, inhibition of rennin secretion, and inhibition of 
neurotransmitter release. 
A1 receptors increase trans-epithelial resistance and reduce Na
+
 uptake in inner 
medullary collecting duct cells in culture. 
Adenosine acts via A1 receptors and inhibition of cAMP to inhibit lipolysis and increase 
insulin sensitivity in adipose tissue. 
A1 receptors have been widely reported to mediate the protective effects of adenosine in 
preconditioning and during ischemia or during reperfusion injury in the heart, lung and 
brain. 
Adenosine contributes to inflammatory reactions via effects on neutrophil and/or 
endothelial A1 receptors. This is done by augmenting responses to microbial stimuli, 
promoting chemotaxis, adhesion to endothelium, phagocytosis, and release of reactive 
oxygen intermediates.
5 
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B: Selective Agonists of A1 Receptors 
Certain N
6
-substituted adenosine derivatives, such as N
6
-cyclopentyladenosine (CPA), 
N
6
-cyclohexyladenosine (CHA) are selective agonists at A1 receptors. Substitutions at 
both the N
6
- and C2-positions have produced 2-chloro-N
6
-cyclopentyladenosine (CCPA) 
which is A1 selective (Fig. 2). N-[1S, trans-2-hydroxycyclopentyl]adenosine (GR79236) 
has been reported to be an A1 selective agonist, which is approximately equipotent with 
CPA in a variety of isolated tissues and cell types.
5 
It appeared that partial agonists for adenosine A1 receptors have been obtained by 
substituting the 8-position of CPA, by removing the 2´-or 3´-hydroxyl group from the 
ribose ring, and by replacing the 5´-hydroxyl group with methylseleno- or methylthio-
group.
7
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Figure 2:  The chemical structures of some selective agonists at A1 receptors. 
 
5.1.2  A2A Receptors 
 
A: Distribution and Biological Effects 
A2A receptors have a wide-ranging but restricted distribution that includes immune 
tissues, platelets, the CNS, and vascular smooth muscle and endothelium.  
 13 
Within the brain, the highest levels of A2A receptors are in the striatum and olfactory 
tubercle (regions which are rich in dopamine). Low levels of A2A receptor also seem to 
be expressed in most other brain regions, although for striatal cholinergic neurons this is 
controversial. Striatal neurons express A2A receptors in close association with dopamine 
D2 receptors and specific negative interactions have been described. Outside the brain, 
the most abundant expression of human A2A mRNA is in immune tissues, eye and 
skeletal muscle; heart, lung, bladder, and uterus also show strong expression, with less 
abundant expression in small intestine, kidney, spleen, stomach, testis, skin, kidney, and 
liver.
5
 
A2A receptors in the CNS and particularly in the peripheral nervous system (PNS) 
generally facilitate neurotransmitter release.  
The negative interactions that have been observed between A2A and dopamine D2 
receptors involve a reduced affinity of agonist binding to dopamine D2 receptors upon 
stimulation of A2A receptors in rat striatal membranes. This raises the possibility of using 
A2A receptor antagonists as a novel therapeutic approach in the treatment of Parkinsons 
disease, to reduce the profound disabling effects arising from degeneration of 
dopaminergic nigrostriatal neurons of the basal ganglia in this disease. 
It was suggested that the receptors do not interact directly to influence agonist binding. 
Interestingly, activation of A2A receptors on rat striatal nerve terminals causes 
desensitization of coexpressed A1 receptors. It is noteworthy that both D2 dopamine and 
A1 adenosine receptors couple to Gi proteins to cause inhibition of adenylate cyclase. 
Thus, with respect to the actions of adenosine at A2A receptors, negative A2A-A1 and A2A-
D2 interactions will shift the balance of intracellular signaling further toward stimulation 
of cAMP.  
In the blood vessels, A2A receptors have been described on both the smooth muscle and 
endothelium, where they are associated with vasodilatation. There seems to be 
considerable variation in A2A receptor expression between blood vessels, although it is 
possible that vessels irresponsive to A2A-selective agonists do express the receptor but at 
very low levels, or that the receptor is not coupled to a functional response. Adenosine 
has a mitogenic effect on endothelial cells, which in human endothelial cells is mediated 
via the A2A receptor and subsequent activation of mitogen-activated protein kinase.
5 
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B: Selective Agonists of A2A Receptors 
A2A receptors do not generally bind N
6
-substituted adenosine derivatives and show a 
preference for derivatives with modifications of the 2nd position of the adenine ring; 
bulky substituents in this position can selectively enhance A2A receptor affinity. Several 
synthetic A2A-selective agonists are modeled according to this structural modification.
 
 The 2-p-(2-carboxyethyl)phenylamino-5'-N-ethylcarboxamido adenosine (CGS 21680) 
is selective for the A2A versus the A1 receptor (Fig.3). CGS 21680 has only very low 
affinity at the A2B receptor, and thus has been used extensively to discriminate between 
A2A and A2B subtypes. 
Amine derivatives of CGS 21680, namely 2-[4-[2-[2-[(4-aminophenyl)methylcarbonyl-
amino]ethylcarbonyl]ethyl]phenyl]ethylamino-5'-N-ethylcarboxamido adenosine (PAPA-
APEC), are A2A-selective.
5
 
CGS 21680
N
N
N
N
NH2
(CH2)2NHHOOC(CH2)2
O
O
OHOH
O
CH3CH2(NH)
 
Figure 3:  The chemical structure of a selective agonist at A2A receptors. 
 
The C2 substituted adenosine derivative displays poor selectivity, but is a valuable 
precursor for the synthesis of more selective A2A receptor agonists. N
6
-(2-(3,5-
dimethoxyphenyl)-2-(2-methylphenyl)ethyl)-adenosine (DPMA) is a selective A2A 
receptor agonist.
5 
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A series of 2-arylalkynyl and 2-heteroalkynyl derivatives of 5'-(N-
ethylcarboxamido)adenosine (NECA) have been studied for their selectivity at the A2A 
receptor. The 2-hydrazinoadenosine, 2-cyclohexylmethylidenehydrazinoadenosine 
(WRC-0470) has been shown to be a potent and selective A2A agonist, with low 
nanomolar affinity at recombinant A2A receptors. 
Selectivity for the adenosine A2A receptor can be obtained by introduction of a 2-
substituent, such as a 1-hexenyl or a (E)-1-hexenyl group that have been shown to induce 
hight affinity for the adenosine A2A receptor compared to A1. Partial agonism for 
adenosine receptor in general has been achieved by the introduction of alkylthio-
substituents at the 5´-position or by removing the 2´-hydroxy group.8 
 
5.1.3 A2B Receptors 
 
A: Distribution and Biological Effects 
A2B receptors are found on practically every cell in most species; however, the number of 
receptors is small and relatively high concentrations of adenosine are generally needed to 
evoke a response. The sensitive technique of reverse transcription-polymerase chain 
reaction (RT-PCR) showed low levels of A2B receptors in all rat brain regions. Northern 
blot analysis
6
 showed relatively high expression of A2B receptors in the caecum, large 
intestine, and urinary bladder, with lower levels in the brain, spinal cord, lung, vas 
deferens, and pituitary. RT-PCR revealed the highest expression of A2B receptors in the 
proximal colon, with lower levels in the eye, lung, uterus, and bladder; still lower levels 
in the aorta, stomach, testis, and skeletal muscle; and the lowest levels in the jejunum, 
kidney, heart, skin, spleen, and liver.   
They have been also immunolocalized and shown to activate human mast cells. This 
implies a possible role in allergic and inflammatory disorders.  
Vascular A2B receptors seem to be important in mediating vasodilatation in some vessels, 
but not in these where the A2A subtype predominates.
5 
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B: Selective Agonists of A2B Receptors 
Despite intensive efforts in this area, there are no A2B-selective agonists. Thus, at present, 
activation of adenylate cyclase in membranes and accumulation of cAMP in cells is used 
to characterize A2B receptors, provided a lack of activity/binding of A1-, A2A-, and A3- 
selective agonists is confirmed. As with A2A receptors, A2B receptors show a preference 
for adenosine derivatives with modifications of the C2 position of the adenine ring. 
NECA is currently the most potent agonist at A2B receptors, but is less useful in 
characterization of A2B receptors in cells or tissues in which A2A receptors are 
coexpressed because it is non-selective. 2-Chloroadenosine (2-ClADO), N
6
-(3-
iodobenzyl)-adenosine-5′-N-methyluronamide (IB-MECA), and N6-(2-phenylisopro-
pyl)adenosine (R-PIA) are among the more potent of other conventional adenosine 
receptor agonists that act also at A2B receptors, but their affinity for the A2B receptor is 
relatively low.
5 
 
5.1.4  A3 Receptors 
 
A: Distribution and Biological Effects 
The A3 receptor is widely distributed. A3 mRNA is expressed in testis, lung, kidney, 
placenta, heart, brain, spleen, liver, uterus, bladder, jejunum, proximal colon, and eye of 
rat, sheep, and humans. The highest levels of human A3 mRNA are found in lung and 
liver, with lower levels in aorta and brain.
6 
The A3 receptor on mast cells facilitates the release of allergic mediators including 
histamine, suggesting a role in inflammation.
5 
The hypotensive response may be caused by the secondary action of histamine released 
after activation of mast cell A3 receptors.  
A3 receptors on human eosinophils and human promyelocytic HL-60 cells seem to be 
involved in apoptosis, an active self-destructive process caused by a genetically 
programmed cascade of molecular events involving DNA degradation and death of the 
cell by nuclear and cytoplasmic breakup. This seems to require high concentrations of 
agonist or chronic activation of the A3 receptor in a manner that mimicks the requirement 
of high levels of ATP to activate the non-specific pore-formation of the P2X7 receptor 
and apoptosis, and suggests that this potentially autocatalytic process may occur during 
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pathological conditions resulting in cell damage and release of high levels of purines. 
Apoptotic effects are caused by high concentrations (micromolar) of A3 receptors of 
agonist in HL-60 leukemia and U-937 lymphoma cells, but paradoxically, A3 receptor 
antagonists also induce apoptotic cell death, and this is opposed by low (nanomolar) 
concentrations of Cl-IB-MECA. This indicates that low-level activation of A3 receptors 
may result in cell protection, and furthermore that this may occur as a consequence of 
endogenously released adenosine. Acute stimulation of A3 receptors with micromolar 
concentrations of Cl-IB MECA has also been shown to cause lysis of granular 
hippocampal neurons in culture.  
A3 receptors may be involved in the cardioprotective effect of adenosine in ischemia and 
preconditioning during ischemia reperfusion injury. Activation of an A3 receptor in 
basophilic leukemia cells, endothelial cells, cardiac myocytes, and smooth muscle cells 
activates the cellular antioxidant defense system by increasing the activity of superoxide 
dismutase, catalase, and glutathione reductase, thereby providing a means by which 
adenosine may have a cytoprotective action in ischemia.
5 
 
B: Selective Agonists of A3 Receptors 
The main class of selective A3 receptor agonists is the N
6
-substituted adenosine-5`-
uronamides. N
6
-(3-iodobenzyl)-5`-(N-methylcarbamoyl)adenosine (IB-MECA) is full 
selective agonist (Fig. 4), which is currently in phase 2 clinical trials for the treatment of 
colorectal cancer and rheumatoid arthritis.
9
  
The iodinated radioligand [
125
I]IB-MECA binds with approximately nanomolar affinity 
to rat brain A3 adenosine receptors expressed in CHO cells, but also binds to native A1 
receptors. Selectivity is increased by 2-substitution of N
6
-benzyladenosine-5`-
uronamides; 2-chloro-IB-MECA (Fig. 4) is highly selective for A3 versus A1 and A2A 
receptors. There is pronounced interspecies differences in the relative affinities of agonist 
binding at A3 receptors.
5 
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Figure 4: The chemical structure of some selective agonists at A3 receptors. 
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5.2 Methods of Nucleoside Synthesis11 
 
There are two major approaches for nucleoside synthesis. One is direct glycosylation of 
natural and/or modified purine and pyrimidine bases and their derivatives; the other is 
construction of purine or pyrimidine rings from simple N-glycosylated precursors. 
Modification of the base, or sugar, or both moieties, has applications in synthesis of 
specific nucleosides. In synthesis of nucleosides by the direct glycosylation, both 
regioisomers and stereoisomers can be formed. The most challenging obstacles involve 
simultaneously achieving regio- and stereocontrol of glycosylation. 
 
5.2.1 General Methods of Nucleoside Synthesis by Direct 
Glycosylation 
 
5.2.1.1 Fischer-Helferich Silver Salt Method and Mercury Salt 
Method 
 
The first synthesis of adenosine and guanosine was accomplished by the Fischer-
Helferich method.
12
 Condensation of 2,8-dichloroadenine silver salt and an acylated 
ribofuranosyl chloride, followed by ammonolysis and reductive dehalogenation gave 
adenosine (Scheme 1). 
The applicability of that method for nucleoside synthesis was limited because of its low 
yield, which was significantly improved by using a chloromercury salt of a base (30-40 
%). The use of mercury salts of purine derivatives gave the nucleosides in relatively good 
yields.
13
 However the mercury method is not used for the preparation of clinical reagents 
due to the difficulty in removing the toxic mercury salts. 
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Scheme 1.  The first synthesis of adenosine by the Fischer-Helferich 
method. 
 
5.2.1.2 Fusion Method 
 
This method was introduced by Sato et al. in 1960.  Heating an acylated sugar and a 
purine (pyrimidine) base in the presence of an acid catalyst at reduced pressure gave 
condensation products (after melting). The reaction usually gave anomeric mixtures. The 
first synthesis of 2-chloro-2’-deoxyadenosine (cladribine, 2-CdA) as a target compound 
was accomplished using a fusion method.
14
 Coupling of 2,6-dichloropurine with 1,3,5-
tri-O-acetyl-2-deoxy-α-D-erythro-pentofuranose gave an anomeric mixture. Fusion of 
2,6-dichloropurine with methyl 2-deoxy-3,5-di-O-(p-toluoyl)-D-erythro-pentofuranoside 
also gave a mixture of both anomers, which was separated by silica gel chromatography. 
Ammonolysis of the 6-Cl group and simultaneous deprotection of the toluoyl groups 
gave 2-CdA with a total yield of 8 %. It was shown that coupling of 1,3,5-tri-O-acetyl-2-
deoxy-α-D-erythro-pentofuranose with purines gave a mixture of α/β-anomers in 
moderate yields.
15
 Coupling of 2,6-dichloro-1-deaza-9H-purine with a 3-deoxyribose 
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derivative by the acid-catalyzed fusion method gave an anomeric mixture of the N9-α/β-
3´-deoxynucleosides (29 % and 52 %, respectively).16 Pedersen et al.17 reported their 
synthesis of pyrimidine 1’-aza-C-nucleosides by fusion of 5-bromouracil, 5- 
bromocytosine and 5-bromoisocytosine with (3R,4R)-4-(hydroxymethyl)pyrrolidin-3-ol 
in 40-41 % yield. 
 
5.2.1.3 Transglycosylation Method 
 
Transglycosylation can occur both intermolecularly and intramolecularly. Intramolecular 
N3 → N9 and N7 → N9 transglycosylations were observed in nucleoside synthesis.18 
Seela et al. reported a thermal N9 → N7 isomerization of 2-N-acetyl-2’-deoxyguanosine 
in a melt and in solution, and a Zwitterionic 7,9-bis(2-deoxy-D-erythro-
pentofuranosyl)guanine intermediate was proposed. The overall intramolecular 
transglycosylation was suggested to occur by an intermolecular reaction, instead of a 
direct migration of the sugar moiety. Intermolecular transglycosylation is a useful 
method for preparation of complicated nucleosides.
18, 19
 The transglycosylation reaction 
proceeds with high stereoselectivity for the β-anomer if the glycosyl donor contains a 2-
α-acyloxy group. Otherwise, the reaction usually gives anomeric mixtures as in direct 
glycosylation. Attempts to prepare 2’-O-methyladenosine by transglycosylation of 3’,5’-
di-O-acetyl-2’-O-methyluridine, or 4-N-acetyl-3’,5’-di-O-acetyl-2’-O-methylcytidine 
with persilylated 6-benzoyladenine were not very successful, and gave β-anomers in 
yields of 30 % and 50 % respectively, with significant amounts of α-anomers.20 A 
method for synthesis of 2’-deoxynucleosides via transglycosylation of 6-oxopurine 
ribonucleosides followed by radical reductive deoxygenation was developed.
21 
Transglycosylation of 2’-O-acetyl-3’,5’-O-(tetraisopropyl-1,3-disiloxanediyl)inosine 
with 6-methylpurine in chlorobenzene with 0.1 equivalent of p-toluenesulfonic acid was 
reported to proceed quantitatively.
21 
 
5.2.1.4 Enzymatic Synthesis 
 
Two types of enzymes have been used, i.e., trans-N-deoxyribosylase and nucleoside 
phosphorylase. Trans-N-deoxyribosylases were used to prepare biologically active 
nucleo-sides such as cladribine
22
 in spite of their limited sources and applications. The 
 22 
application of phosphorylase was described earlier. Krenitsky had noted the enzymatic 
equilibrium-transfer reaction of the sugar moiety of one nucleoside to a different 
heterocyclic base. Purine nucleoside phosphorylase (PNPase) catalyzes the equilibrium-
transfer reaction between purine nucleosides and purines. Transglycosylations using 
these enzymes as catalysts have recently been applied to the synthesis of biologically 
active purine nucleosides. 
 
5.2.1.5  Vorbrüggen Glycosylation (Silyl-Hilbert-Johnson 
Method) 
 
The Vorbrüggen glycosylation23 and its variations involving the reaction of persilylated 
bases with glycosyl donors under Lewis acid conditions have been used to prepare many 
modified nucleosides. This method is particularly useful when there is α-acyloxy group 
at C-2 of the glycosyl donor, producing β-nucleosides in a stereocontrolled manner 
because of the neighboring group participation. In the case of 2’-deoxynucleosides, 
however, no such participation is present; thus, anomeric mixtures of varying ratios 
result which are often difficult to separate. For purines, there is also a problem of 
regioselectivity as in the transglycosylation methods. 
The mechanism of the glycosylation of benzimidazole is given in Scheme 2.
24 
1,2,3,5-
tetra-O-acetyl–β-D-ribofuranose (1) is set up with Lewis acid, trimethylsilyltrifluoro-
methane sulphonate (TMSOTf). Than the sugar builds a cation (2) through an 
intramolecular attack of the 2-acetyl group on C1 position and at the same time the acetyl 
group leaves. The C1-acetyl group leaves the reaction as trimethylsilylacetate ester. 
Therefore five membered ring, in α position of the sugar ring, is formed. When the sugar 
cation is added to the silylated base solution, this nucleophile attacks the sugar-cation on 
C1. The attack can only be on the β side of the sugar ring. After the attack on the five 
membered ring, which is formed with an intramoleculare reaction of the C2-acetyl group, 
the ring is again opened and a nucleobase is covalently bonded to the sugar ring.
 
The big advantage of this reaction is that only β-nucleoside can be formed.  
 23 
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Scheme 2.  Glycosylation Reaction.24 
 
5.2.1.6 Sodium Salt Method 
 
The sodium salt method has been utilized for the synthesis of acyclic, furanosyl and 
pyranosyl nucleosides. A sodium salt of a purine was formed in situ, and treated with a 
halosugar as the glycosyl donor. For the synthesis of 2’-deoxynucleosides, stereospecific 
 24 
formation of the β-isomer requires the SN2 pathway completely with exclusion of 
anomerization of the α-chlorosugar. Due to the availability of crystalline 2-deoxy-3,5-di-
O-(p-toluoyl)-α-D-erythro-pentofuranosyl chloride, many groups have effected coupling 
of this sugar derivative with different bases via SN2 displacement of chloride. Earlier 
studies claimed that glycosylation of the sodium salt of acidic heterocycles with this 
sugar chloride in CH3CN at ambient temperature gave exclusively β-anomer, or β-
anomers of regioisomers (N9/N7 for a purine).
25
 Coupling of this protected 2-deoxy 
chlorosugar with the sodium salt of 6-chloropurine and 2,6-dichloropurine was reported 
to give a mixture of two β-isomers, the N7 and N9 nucleosides (Scheme 3). 
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                                                      X=Cl          (59 %)     (13 %) 
                                                      X=H           (59 %)     (11 %)     
 
Scheme 3.  Synthesis of 2’-deoxynucleosides by the Sodium Salt metod. 
 
The best results were obtained with CHCl3 as the reaction medium.
26
 When the 
chlorosugar was allowed to anomerize in CH3CN before addition of the base, the α-
nucleoside was produced exclusively. 2-Amino-6-chloropurine gave a mixture of β-
isomers (9β/7β ~3:1). Protection of the NH2 group with an N, N-dibutylformamido group 
gave an even poorer result (9β/7β/3β ~1.0:0.9:0.5) with the N9-β-nucleoside as the major 
product (29 %). The formation of α-anomers was not mentioned. 
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5.2.2 Strategies for Stereoselective Glycosylation of 2-
Deoxy-D-erythro-pentofuranose Derivatives 
 
As shown above, glycosylation of the sodium salts of hetereocyclic bases with crystalline 
2-deoxy-3,5-di-O-(p-toluoyl)-α-D-erythro-pentofuranosyl chloride via the SN2 pathway 
is a convenient and efficient method for synthesis of 2’-deoxynucleosides, although the 
stereoselectivity varies with the structure of the bases and reaction conditions. In recent 
attempts for Lewis acid catalyzed glycosylation, the most dominant concept hinges on 
1,2-trans glycosylation with temporarily installed 2-α substituents such as benzylthio,27 
phenylthio,
28
 phenylselenenyl,
29
 or iodo
30
 functioning as neighboring groups, followed 
by removal of such groups via reduction or elimination. An alternative with 3-α 
substituents is generally less successful.
31 
 
5.2.2.1 Anchimeric Assistance of 2-α-Substituents 
 
An earlier application of this strategy was the synthesis of purine 2’-α-thio-2’- 
deoxynucleosides (Scheme 4).
27
 Both, the yields and selectivity were poor. 
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Scheme 4.  Anchimeric assistance of the 2’-α-benzylthio group in acid 
                    catalyzed glycosylation. 
 
The ratio of products was not dependent on temperature. It was observed that SnCl4 was 
a better Lewis acid than TMSOTf.  
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5.2.3 Strategies for Regioselective Alkylation and 
Glycosylation of Purines 
 
 
Alkylation and glycosylation of purines are rarely regiospecific, and give rise to mixtures 
of N9 and N7 products. Glycosylation of persilylated 6-N-benzoyladenine with a 
dioxabicylco[3.2.1]octane at ambient temperature gave both N9 and N7 products, and it 
was suggested that the N7 isomer was the kinetic product. It was converted into the N9 
isomer at elevated temperature in the presence of TMSOTf. 
 
5.2.3.1 6-Functional Groups for Regioselective N9 Alkylation 
and Glycosylation of Purines 
 
The Saneyoshi and Satoh method of glycosylation with SnCl4 is usually used for 
regioselective glycosylation of adenine.
32
 Yields >75 % are accessible. With 2-
aminopurines, the ratio of N9 to N7 alkylation was influenced by the size of the 6-
substituents on the purine ring, and larger groups at C-6 lead to increased ratios.
33
 Bulky 
protecting groups installed on C6 substituents were used to improve the selectivity of N9 
alkylation.
34
 For example, Geen et al.
35
 studied the effects of 6-substituents 
systematically. Variation of 6-functional groups was tried to improve the N9/N7 
regioselectivity of glycosylation. They found the ratio of N9 to N7 alkylation ranged 
from 1.8:1 (6-methoxy-2-aminopurine) to 25:1 (6-isopropyl-2-aminopurine), using 
K2CO3 as the base in DMF.
 
Reese et al.
34
 reported a highly regioselective N9 alkylation of 2-amino-6-[(4- 
chlorophenyl)sulfanyl]purine in the presence of K2CO3 in DMF with 4-acetoxy-3- 
acetoxymethylbutyl mesylate (89:11 regioselectivity for N9 product in 80 % yield).
 
Lower regioselectivity was observed for 2-amino-6-chloropurine (N9/N7, 82:18). 
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5.2.4 Synthesis of 2-Chloro-2’-deoxyadenosine 
 
                  
N
N
N
N
NH2
Cl
O
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OH   
 
2-Chloro-2’-deoxyadenosine (cladribine, 2-CdA) is a purine 2’-deoxynucleoside 
analogue with a 2-chloro substituent on the purine ring, systematic name 5-(6-amino-2-
chloro-purin-9-yl)-2-(hydroxymethyl)oxolan-3-ol. It is resistant to deamination by 
adenosine deaminase (ADA) due to its protonation at N7 instead of N1, which prevents 
addition of water and deamination at C6.
35 
Cladribine was first prepared by Venner in Fischer-Helferich syntheses of 2’- 
deoxyuncleosides in 1960. It was an intermediate for synthesis of both 2’-
deoxyguanosine and 2’-deoxyinosine. 
Ikehara et al.
36
 also employed 2-CdA as an intermediate in the preparation of 2’-
deoxyadenosine. In the latter example, 2-CdA was obtained by coupling the mercury salt 
of 2,8-dichloroadenine with 2-O-acetyl-3-O-tosyl-5-O-methoxycarbonyl-D-xylofurano-
sylchloride, followed by indirect deoxygenation via desulfurization of 8,2’-anhydro-9-(β-
D-arabi-nofuranosyl)-2-chloro-8-thioadenine. 
As a target compound, Robins et al.
37
 coupled 2,6-dichloropurine with 1,3,5-tri-O-acetyl- 
2-deoxy-α-D-erythro-pentofuranose using the fusion method to give an anomeric 
mixture. Regiospecific ammonolysis of the 6-Cl group and the protecting esters gave 2-
CdA and its α-isomer. This mixture was reacylated with p-toluoyl chloride and separated 
by chromatography. Deprotection in methanolic sodium methoxide at ambient 
temperature gave 2-CdA with an overall yield of 16 %. Fusion of 2,6-dichloropurine with 
methyl 2-deoxy-3,5-di-O-(p-toluoyl)-D-erythro-pentofuranoside gave a mixture of 
anomers, which was separated by silica gel chromatography. Ammonolysis of the 6-Cl 
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group and simultaneous deprotection of the p-toluoyl groups gave 2-CdA with an overall 
yield of 8 %. 
The current industrial procedure to prepare 2-CdA was devised by Robins et al.
38
 via 
direct glycosylation. Direct glycosylation of 2-deoxyfuranose derivatives invariably 
gives anomeric mixtures, and both N7 and N9 can be glycosylated to give regioisomers. 
The similar mobility of these isomeric products during chromatographic separation 
causes difficulties for purification. Yields of the desired products are usually low.  
In the Robins procedure, the sodium salt of 2,6-dichloropurine was prepared in situ by 
treatment with NaH in CH3CN at ambient temperature. This salt was coupled with 2-
deoxy-3,5-di-O-(p-toluoyl)-α-D-erythro-pentofuranosyl choride in CH3CN to give a 
mixture of β-anomers (N9 and N7) in yields of 59 % and 13 %, respectively. A more 
detailed study by Hildebrand and Wright
39
 discovered that both α- and β-anomers were 
formed, and yields of 50 %, 15 % and 1.5 % were obtained for the 9-β-, 7-β- and 9-α- 
nucleosides, respectively. The formation of N7 coupling products resulted from the 
ambident character of the sodium salt of the purine. Chromatographic separation of the 
mixture gave 2,6-dichloro-9-[2-deoxy-3,5-di-O-(p-toluoyl)-β-D-erythro-pentofuran-
osyl]purine, which was ammonolyzed with methanolic ammonia at 100 °C to give 2-
CdA in an overall yield of 42 %. The Robins procedure has been further modified to 
improve both the regioselectivity for N9 isomer and the stereoselctivity for the β-anomer 
by altering the purine aglycon and changing the reaction medium.  
Kazimierczuk and Kaminski
40
 prepared 2-CdA by condensation of 2-chloropurine 
derivatives (6-alkoxy, halo, alkylthio, etc.) with 2-deoxy-3,5-di-O-aroyl-α-D-erythro-
pentafuranosyl chlorides (aroyl = p-chlorobenzoyl, p-bromobenzoyl, p-methoxybenzoyl, 
p-nitrobenzoyl, 2,4-dinitrobenzoyl) in the presence of alkali metal hydrides or hydroxides 
and phase-transfer catalysts, followed by ammonolysis and deprotection. Neither 
procedure excluded the formation of N7-isomers.  
Gerszberg and Alonso
41
 reported a synthesis of cladribine using the sodium salt method 
with acetone as solvent. By controlling the reaction time, high stereoselectivity was 
attained by sacrificing the yield. The low yield (30 % based on 2-chloroadenine) 
probably resulted from the low solubility of the sodium salt of 6-amino-2-chloropurine. 
The high regioselectivity might have been enhanced by intermolecular hydrogen bonding 
between the 6-amino group of the purine and acetone. 
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The second major method for preparation of 2-CdA is by modification of natural 
nucleosides. Chen
42
 prepared 2-CdA from guanosine in a low overall yield (2.8 % for 8 
steps). 2’,3’,5’-Tri-O-acetylguanosine was deoxychlorinated at C6; subsequent 
diazotization/chloro-dediazonia-tion, and ammonolysis gave 2-chloroadenosine. 
Protection of the 3’- and 5’-OH groups as 3’,5’-O-tetraisopropyldisiloxyl, and acylation 
of the 2’-OH group with phenyl chlorothionofor-mate, followed by radical 
deoxygenation with an organic tin hydride and desilylation gave 2-CdA.  
Robins et al.
27
 reported a concise synthesis of 2-CdA from the more expensive 2’-deoxy-
guanosine. Transformation of the 6-oxo group to 6-Cl and/or 6-O-arylsulfonyl, 
diazotization/chloro-dediazoniation at C2, followed by ammonolysis at C6 and 
simultaneous deprotection of the sugar moiety gave 2-CdA in good overall yields (64-75 
%). 
A third method for preparation of 2-CdA employed enzymatic glycosyl transfer. 
Mikhailopulo et al.
43
 reported an enzymatic synthesis by direct transfer of the 2- 
deoxyfuranose moiety of thymidine to 2-chloroadenine using a trans-N-deoxyribosylase.  
Barai et al.
44
 described a similar glycosyl transfer from 2’-deoxyguanosine to 2-
chloroadenine with a large excess of 2’-deoxyguanosine, which gave a low yield (<27 %) 
based on 2’-deoxyguanosine. Thus, there is a great need for cost effective methods to 
prepare 2-CdA in high yields. A regiospecific and highly stereoselective glycosylation 
for synthesis of 9-(2-deoxy-β-D-erythro-pentofuranosyl)purine nucleosides has been 
developed above.  
The strategies of using binary solvent mixtures for glycosylation, and increase of purine 
solubility by introduction of lipophilic groups have been applied to the synthesis of 
cladribine. 
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6 EXPERIMENTAL PART 
 
6.1 General experimental details 
 
A reaction with 2,6-dichlorpurine was carried out under atmosphere of nitrogen and 
glassware was oven-dried overnight. Dry solvents (CH2Cl2, CH3CN, CHCl3 and CH3OH) 
in Sure Seal bottles and reagents were purchased from Fluka and Aldrich without further 
purification. Reagents and solvents were of commercial grade (Aldrich Chemical Co).  
Reactions were monitored by TLC using silica gel plates Polygram® Sil G/UV 254 
(40×80 mm).  Silica gel (400 mesh) for flash chromatography (FC) was from Merck. 
1
H and 
13
C NMR data were acquired, at room temperature, on a Bruker AMX 500 NMR 
spectrometer operating at 500.13 and 125.77 MHz, respectively. Dimethylsulfoxide-d 6 
was used as a solvent; chemical shifts are expressed in  (ppm) values relative to 
tetramethylsilane (TMS) as internal reference; coupling constants (J) are given in Hz. 
Assignments were also made from DEPT (distortionless enhancement by polarization 
transfer) (see underlined values). Melting points were obtained on a Köfler microscope 
(Reichert Thermovar) and are uncorrected. 
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6.2 Synthetic details 
 
6.2.1 2,6-dichloro-9H-(2,3,5-tri-O-benzoyl-β-D-
ribofuranosyl)purine 
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To a stirred mixture of 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (3) ( 3,076 g, 
5,3 mmol, 580,3 g/mol), 2,6-dichlorpurine (4) (1,0092 g, 5,3 mmol, 188,68 g/mol), and 
1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (2,2 mL, 14,8 mmol) in anhydrous 
acetonitrile (22 mL) cooled at 0 °C under a nitrogen atmosphere was slowly added 
Me3SiOTf (3,75 mL, 18,5 mmol). The solution was orange coloured and white gas was 
escaped of the solution by addition of Me3SiOTf. The resulting mixture was heated at 60 
°C for 4,5 hours (the solution was coloured to brown), cooled to room temperature, and 
shaken between NaHCO3 (1M) and CH2Cl2. The organic layer was separated and dried 
over anhydrous Na2SO4. The solvent was evaporated to dryness, and the light brown 
crude residue was washed in water to provide a white solid (5) (2,886 g, 4,6 mmol, 86 
%). 
Molecular Formula C31H22Cl2N4O7 
Molecular Weight 633.44 
Yield: 2,89 g ( 86 % ) 
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Melting Point: 61-64 °C (Literature features 75-78°C)45 
TLC Rf 0.25 (n-hexane-EtOAc 7:3) 
 
                 1
H NMR (500 MHz, DMSO d6): δ (ppm) 8,97 (s, 1H), 7,95-7,86 (m, 6H), 7,71-
7,58 (m, 3H), 7,51-7,38 (m, 6 H), 6,71-6,66 (m, 1H), 6,37-6,31 (m, 1H), 6,24-6,18 (m, 
1H), 4,95-4,88 (m, 1H), 4,82-4,76 (m, 1H), 4,73-4,66 (m, 1H), 3,57-3,51 (m, 1H), 3,49-
3,42 (m, 1H). 
                  13
C NMR (125 MHz, DMSO d6): δ (ppm) 165, 164, 152, 151, 150, 147, 133, 
131, 129, 87, 80, 74, 71, 63.  
 
6.2.2 6-Amino-2-chloro-9H-(β-D-ribofuranosyl)purine        
(6-Amino-2-chloropurine riboside) 
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2,6-Dichloro-9H-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)purine (5) (1,0110 g, 1,6 mmol)  
was treated with methanolic ammonia (19,24 mL) saturated at 0 °C and stirred at room 
temperature for 25 hours in a pressure bottle. The resulting mixture was evaporated to 
dryness, and the crude product was purified by flash chromatography using gradient 
elution from chloroform-methanol (9:1) to chloroform-methanol (6:4). The solvents were 
evaporated under reduced pressure and it was obtained a white solid (6) (0,292 g, 1 
mmol, 60 %). 
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Molecular Formula C10H12ClN5O4 
Molecular Weight 301,69 
Yield: 0,292 g (60 %) 
Melting Point:122-125 °C (Literature features 133-136°C)46 
TLC Rf 0.29 (chloroform-methanol 8:2) 
                 1
H NMR (500 MHz, DMSO d6): δ (ppm) 8,67 (s, 1H), 8,38 (s, 2H, -NH2), 5,80 
(d, J=6,0, 1H), 5,52 (d, J=6,1, 1H), 5,24 (d, J=4,7, 1H), 5,10 (t, J=5,6, 1H), 4,65-4,35 
(m, 1H), 4,22-4,01 (m, 1H), 3,98-3,85 (m, 1H), 3,72-3,59 (m, 1H), 3,57-3,46 (m, 1H). 
                   13
C NMR (125 MHz, DMSO d6): δ (ppm) 157, 153, 150, 140, 118, 87, 86, 74, 
70, 61. 
 
A second product of the reaction,  a white solid (7) (0,080 g, 0, 25 mmol, 16 %) 
was characterized.  
 
Molecular Formula C11H13ClN4O5 
Molecular Weight 316,17 
Yield: 0,080 g (16 %) 
Melting Point: 95-98 °C 
TLC Rf 0.48 (chloroform-methanol  8:2) 
                 1
H NMR (500 MHz, DMSO d6): δ (ppm) 8,65 (s, 1H), 5,91 (d, J=5,6, 1H), 5,52 
(d, J=6,1, 1H), 5,23 (d, J=5,2, 1H), 5,03 (t, J=5,5, 1H), 4,54-4,47 (m, 1H), 4,18-4,09 (m, 
1H), 4,1 (s, 3H), 4,02-3,91 (m,1H), 3,71-3,62 (m, 1H), 3,60-3,51 (m, 1H). 
                13
C NMR (125 MHz, DMSO d6): δ (ppm) 161, 153, 152, 143, 120, 88, 86, 74, 70, 
61, 55. 
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6.2.3 2-Chloro-6-isobutylamino-9H-(β-D-
ribofuranosyl)purine                                                       
(2-Chloro-N-isobutyladenosine)  
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2,6-Dichloro-9H-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)purine (5) (1,0016 g, 1,6 mmol, 
633,44 g/mol) was treated with a solution of isobutylamine and stirred at room 
temperature for 48 hours in a pressure bottle. The reaction was checked by TLC (CHCl3-
MeOH 9:1). It was obtained mixture of materials. The mixture was evaporated to 
dryness, and the residue was purified by flash chromatography on silica gel, it was 
started with CH2Cl2-MeOH 9:1 as a mobile phase, by gradually addition MeOH  
(CH2Cl2-MeOH 8,5:1,5; 8:2; 7,5:2,5; 7:3; 6,5:3,5; 6:4). The solvents were evaporated 
under reduced. A white solid was obtained (8) (0,312 g, 1.6 mmol, 55 %). 
 
Molecular Formula C14H20ClN5O4 
Molecular Weight 357,79 
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Yield: 0,312 g (55 %) 
Melting Point: 151-154 °C (Literature features 168-170 °C)47 
TLC Rf 0.5 (chloroform-methanol  8:2) 
                 1
H NMR (500 MHz, DMSO d6): δ (ppm) 8,38 (s, 1H), 7,97 (s, 1H, -NH-), 5,81 
(d, J=6,0, 1H), 5,48 (d, J=5,0, 1H), 5,20 (d, J=4,5, 1H), 5,07 (t, J=5,4, 1H), 4,53-4,48 
(m, 1H), 4,15-4,09 (m, 1H), 3,97-3,90 (m, 1H), 3,69-3,61 (m, 1H), 3,58-3,49 (m, 1H), 
3,29-3,20 (m, 1H), 2,59 (d, J=6,9, 2H), 1,91-1,75 (m, 1H), 0,91 (d, J=6,6, 6H). 
 13
C NMR (125 MHz, DMSO d6): δ (ppm) 155, 153, 150, 140, 119, 87, 86, 74, 70, 
61, 28, 26, 20 
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7 RESULTS AND DISCUSSION 
 
The synthesis of 2,6-dichloro-9H-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)purine was 
accomplished by Hocek et al. in 2002.
45
 Condensation of 2,6-dichloro-7(9)H-purine and 
1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose in the presence of SnCl4 gave a 
relatively good yield (52 %). 
My laboratory work was concentrated on the synthesis of 2-chloroadenosine derivatives 
by a method of Franchetti et al.
48
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Scheme 5.  The synthesis of 2-chloronucleosides by Franchetti et al. (a) 
Me3SiOTf/CH3CN, DBU; (b) NH3 / MeOH; (c) cyclopentylamine/EtOH. 
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This method was used for the synthesis of 2,6-dichloro-9H-(2-C-methyl-2,3,5-tri-O-
benzoyl-β-D-ribofuranosyl)purine (10) as shown in  Scheme 5. Coupling of 1,2,3,5-
tetrabenzoyl-2-C-methyl-β-D-ribofuranose (9) and 2,6-dichloropurine (4) with 
trimethylsilyl trifluoromethane-sulfonate in acetonitrile in the presence of DBU gave the 
nucleoside intermediate which was debenzoylated with methanolic ammonia to afford 2-
chloro-9H-(2-C-methyl-β-D-ribofuranosyl)adenine (11) and with cyclopentylamine in 
EtOH to afford N
6
-cyclopentenyl-2-chloro-9H-(2-C-methyl-β-D-ribofuranosyl)adenine 
(12). 
The reaction of 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (3) and 2,6-
dichlorpurine (4) is carried out in a suitable solvent, such as acetonitrile in the presence 
of a silylating agent such as trimethylsilyl trifluoromethanesulfonate and a base such as 
diazabicyclo [5.4.0] undec-7-ene (DBU). 
A first step in the synthesis of 2-chloronucleosides is the condensation of the nucleobase 
and to form the N-glycosidic bond. 
The Silyl-Hilbert-Johnson reaction begins with silylation of the 2,6-dichlopurine and 1-
O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose is set up with Lewis acid, TMSOTf. Than 
the sugar builds a cation (α-ribofuranosyl triflates) (13) through an intramolecular attack 
of the 2-acetyl group on C1 position and at the same time the acetyl group leaves. The 
C1-acetyl group leaves the reaction as trimethylsilylacetate ester. Therefore five 
membered ring, in α position of the sugar ring, is formed (Scheme 6). 
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 Scheme 6. Silylations of 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose 
 
When the sugar cation (13) is added to the silylated base solution, this nucleophile 
attacks the sugar-cation on C1. The attack can only be on the β side of the sugar ring. 
After the attack on the five membered ring, which is formed with an intramoleculare 
reaction of the C2-benzoyl group, the ring is again opened and a nucleobase is covalently 
bonded to the sugar ring (Scheme 7). 
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Scheme 7. Glycosylation reaction 
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Glycosylation of purines are rarely regiospecific, and give rise to mixtures of N9 and N7 
products. N7 isomer was converted into the N9 isomer via an N7, N9 
bis(ribofuranosyl)nucleoside intermediate at elevated temperature in the presence of 
TMSOTf. Finally the N9 β-isomer was obtained as the major product. 
A reaction was carried out under atmosphere of nitrogen and that had effect on an 
obtaining of a higher yield (86 %). The reaction was complete in 4,5 h. 
A second step in the synthesis of 2-chloronucleosides is a deprotection and ammonolysis 
of the 6-Cl group. For example, Vittori et al.
7
 observed, that treatment of 2,6-dichloro-9-
(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)purine with appropriate cycloalkylamine, at room 
temperature for 4 h, gave a mixture of mono-, di-, and triacetylated 2-chloro-N-
substituted derivatives; to accelerate the deacetylation process and to avoid side 
reactions, the crude material was treated with methanolic ammonia at room temperature 
to obtain the desired nucleosides. 
Cappellacci et al.
4
 provided, that nucleophilic displacement of the 6-chlorine atom in the 
protected compounds as 2,6-dichloro-9H-(2-C-methyl-2,3,5-tri-O-benzoyl-β-D-
ribofuranosyl)-purine (10) and 2,6-dichloro-9-(3-C-methyl-2,3-di-O-acetyl-5-O-benzoyl-
β-D-ribofuranosyl)-purine with cyclopentylamine, cyclohexylamine, benzylamine, or 3-
iodobenzylamine in anhydrous ethanol gave, after deprotection with methanolic 
ammonia, the corresponding N
6
-substituted nucleosides. 
In my laboratory work, two common methods for the ammonolysis and the deprotection 
of benzoylated nucleosides are. The first one is using a methanolic ammonia solution 
(Nielson et al., 1971) and the second one is isobutylamine in dry methanol (20 %). 
Ammonolysis of the 6-Cl group and simultaneous deprotection of the benzoyl groups 
with methanolic ammonia solution gave 2-chloroadenosine (6) with a total yield of 60 %. 
The same reaction with isobutylamine in methanol gave 2-chloro-N
6
-isobutyladenosine 
(8) with total yield of 55 % (Scheme 8). 
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Scheme 8.  Deprotection (a) NH3 / MeOH  (b) isobutylamine / MeOH (20%). 
 
2-Chloroadenosine and 2-chloro-N
6
-isobutyladenosine are used as a starting material for 
the modification of nucleosides and for cytobiology research. 2-Chloroadenosine is a 
metabolically stable analog of adenosine which acts as a selective A1 adenosine receptor 
agonist. 
In a next part of this thesis, it was tried to obtain 2-chloro-adenosine derivatives by using 
1,2,3,5-tetra-O-acetyl-β-D-ribofuranose (14) and 2,6-dichloropurine (4) as starting 
materials (Scheme 9).  
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 Scheme 9.  (a) p-toluenesulfonic acid, 20 °C (b) Me3SiOTf, DBU, 60 °C 
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 The synthesis of Qu and Liu
49
 starting from tetra-O-acetyl-β-D-ribofuranose (14) and 
2,6-dichloropurine (4) , in the presence of p-toluenesulfonic acid (p-TsOH), 2',3',5'-tri-O-
acetyl-2,6-dichloropurine nucleoside (15) has been done in microwave oven for the first 
time. As compared with the conventional methods, this method has advantages such as 
shorter reaction time (4.5 min) and better yield (83.5 %). 
The method of Franchetti et al.
48
 was not of advantageous to obtain 2-chloro-adenosine 
derivatives by using 1,2,3,5-tetra-O-acetyl-β-D-ribofuranose (14) as start material 
because mixture of materials was established. The overall yield was declined by resulting 
purification. 
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8 CONCLUSION 
 
This thesis describes the synthesis of nucleosides and their analogues that are of 
enormous importance. They are an established class of clinically useful medicinal agents, 
possessing antiviral and anticancer activity. 
From a chemical point of view, in this work, we focus on the synthesis of adenosine and 
nucleoside analogues. In the adenosine nucleoside series the purine base was altered at 
the 2- and N
6
-position. 
In the method developed by Vorbrüggen, the glycosidic bond formation is driven by the 
use of 2,6-dichlorpurine and 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose in 
combination with strong Lewis acids, like trimethylsilyl trifluoromethanesulfonate and a 
base diazabicyclo [5.4.0]undec-7-ene. This Vorbrüggen coupling reaction is the reference 
in nucleoside synthesis and provides a highly reproducible method for 2,6-dichloro-9H-
(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)purine formation in high yield (86 %) with 
reliable and predictable stereochemistry, i.e. orientation of the glycosidic bond. 
Displacement of the 6-chloro atom in 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose 
with ammonia or isobutylamine, followed by deprotection, produced the 2-
chloroadenosine and the 2-chloro-N
6
-isobutyladenosine. 
2-Chloroadenosine and 2-chloro-N
6
-isobutyladenosine are used as a starting material for 
the modification of nucleosides and for cytobiology research. 2-Chloroadenosine is a 
metabolically stable analog of adenosine which acts as a selective A1 adenosine receptor 
agonist. 
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9 SUMMARY IN CZECH LANGUAGE 
(Shrnutí) 
 
Diplomová práce „Development of selective agonists of adenosine receptors 
optimization of the synthetic procedures to obtain 2-chloropurine and analogues“ byla 
vypracována v rámci projektu Socrates/Erasmus na Faculdade de Farmácia Universidade 
do Porto. 
Práce je zaměřena na syntézu selektivních agonistů adenosinových receptorů. 
Adenosin je důležitá signální molekula, která aktivací adenosinových receptorů P1 
vyvolává různé biologické odpovědi. Jsou známy čtyři typy P1 receptorů: A1, A2A, A2B a 
A3. 
Adenosin reguluje prostřednictvím svých receptorů řadu procesů v lidském organismu, 
každý z receptorů vyvolává na stejný podnět různou reakci. Modifikací adenosinu se 
získávají selektivní agonisté adenosinových receptorů o různé aktivitě a afinitě 
k uvedeným receptorům, v závislosti na jejich struktuře.  
Mým úkolem byla cílená syntéza N6-substituovaného derivátu, který by zároveň 
obsahoval chlor na C2. 
Syntetická práce se zpočátku soustředila na získání 2,6-dichlor-9H-(2,3,5-tri-O-benzoyl-
β-D-ribofuranosyl)purinu (5) a 2,6-dichlor-9H-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-
purin z komerčně dostupných sloučenin.  
V dalším kroku byly chránící benzylové skupiny 2,6-dichlor-9H-(2,3,5-tri-O-benzoyl-β-
D-ribofuranosyl)purin odštěpeny a atom chloru na C6 nahrazen aminoskupinou. 
Konečnými produkty byly 6-amino-2-chlor-9H-(β-D-ribofuranosyl)purin (6) a 2-chlor-6-
isobutyl-amino-9H-(β-D-ribofuranosyl)purine (8). 
2-Chloradenosin (6) je metabolicky stabilním analogem adenosinu, zároveň vykazujícím 
afinitu k A1 adenosinovým recptorům. Z 2-chloradenosinu i 2-chlor-N
6
-isobutyl-
adenosinu (8) mohou být modifikací získány další selektivní agonisté adenosinových 
receptorů. 
Všechny uvedené látky byly už dříve popsány a získány jinými postupy. 
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